BIREN TECH (06082) released its annual performance. Revenue reached 1.035 billion yuan, a year-on-year increase of 207.2%.
Wallace Technology (06082) released the full year performance for the year ended December 31, 2025. The group's revenue was RMB 1.035 billion, a year-on-year increase of 207.2%; gross profit was RMB 557 million, a year-on-year increase of 210.8%; research and development expenses were RMB 1.476 billion, a year-on-year increase of 78.5%.
BIREN TECH (06082) released its annual performance for the year ending December 31, 2025, with a total revenue of 1.035 billion yuan, an increase of 207.2% year-on-year; gross profit of 557 million yuan, an increase of 210.8% year-on-year; and research and development expenses of 1.476 billion yuan, an increase of 78.5% year-on-year.
In 2025, the global artificial intelligence industry is at a critical turning point from technological breakthroughs to large-scale implementation. The company seizes the industrial opportunities, focusing on full-stack independent innovation to achieve strong growth in its business; achieving a series of major milestones in product iteration, technological breakthroughs, and ecosystem development, further strengthening commercial capabilities and ecological cooperation, laying a solid foundation for future development.
In terms of financial position, as of the end of the reporting period, the company held a total of 2.896 billion yuan in cash and cash equivalents, bank deposits, restricted cash, and liquid financial assets measured at fair value with changes in fair value recognized in profit or loss. Together with the net proceeds of 5.631 billion yuan from the listing of the company's H shares on the Hong Kong Stock Exchange in early 2026, the company has sufficient funds to support ongoing technological research and development, capacity expansion, and business implementation. Inventories amounted to 949 million yuan to address downstream demand growth and ensure supply chain resilience. The company, with its continuous product and technological innovation, strong implementation capabilities, and robust financial performance, fully demonstrates its core capabilities of efficient strategic implementation and sustainable growth in a rapidly changing market environment.
Related Articles

XD Inc (02400) spent HK$7.8768 million on March 30 to repurchase 125,000 shares.

EPI (HOLDINGS)(00689) releases annual performance results, with a net profit attributable to shareholders of HKD 5.719 million, turning from a loss to a profit year-on-year.

HEALTHYWAY INC (02587) released its 2025 annual performance report, with a net profit of 54.338 million yuan, achieving a turnaround from loss to profit compared to the previous year.
XD Inc (02400) spent HK$7.8768 million on March 30 to repurchase 125,000 shares.

EPI (HOLDINGS)(00689) releases annual performance results, with a net profit attributable to shareholders of HKD 5.719 million, turning from a loss to a profit year-on-year.

HEALTHYWAY INC (02587) released its 2025 annual performance report, with a net profit of 54.338 million yuan, achieving a turnaround from loss to profit compared to the previous year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


